Compare Aditya Birla Sun Life Pharma & Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Risk | Very High | Very High |
Rating | 2.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.3 | 1.87 |
NAV | ₹30.52 | ₹39.64 |
Fund Started | 20 Jun 2019 | 25 Jun 2018 |
Fund Size | ₹853.63 Cr | ₹6459.82 Cr |
Exit Load | Exit load of 1% if redeemed within 30 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
2.0
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
2.3
1.87
NAV
₹30.52
₹39.64
Fund Started
20 Jun 2019
25 Jun 2018
Fund Size
₹853.63 Cr
₹6459.82 Cr
Exit Load
Exit load of 1% if redeemed within 30 days.
Exit load of 1% if redeemed within 15 days.
1 Year | -0.87% | 3.14% |
3 Year | 21.00% | 27.34% |
5 Year | 13.86% | 17.86% |
1 Year
-0.87%
3.14%
3 Year
21.00%
27.34%
5 Year
13.86%
17.86%
Equity | 97.67% | 97.70% |
Cash | 2.33% | 2.30% |
Equity
97.67%
97.70%
Cash
2.33%
2.30%
Top 10 Holdings |
|
|
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 12.47% |
Apollo Hospitals Enterprise Ltd. | 7.30% |
Cipla Ltd. | 6.76% |
Lupin Ltd. | 4.79% |
Abbott India Ltd. | 4.56% |
Torrent Pharmaceuticals Ltd. | 4.47% |
JB Chemicals & Pharmaceuticals Ltd. | 4.31% |
Aurobindo Pharma Ltd. | 4.19% |
Fortis Healthcare Ltd. | 4.07% |
Ajanta Pharma Ltd. | 3.88% |
Sun Pharmaceutical Industries Ltd. | 12.83% |
Dr. Reddy's Laboratories Ltd. | 9.81% |
Cipla Ltd. | 8.00% |
Divi's Laboratories Ltd. | 7.48% |
Aurobindo Pharma Ltd. | 6.04% |
Lupin Ltd. | 5.70% |
Mankind Pharma Ltd. | 5.04% |
Alkem Laboratories Ltd. | 3.78% |
Syngene International Ltd. | 2.97% |
Cohance Lifesciences Ltd. | 2.68% |
Name | Dhaval Joshi | Dharmesh Kakkad |
Start Date | 10 Jun 2024 | 23 Feb 2021 |
Name
Dhaval Joshi
Dharmesh Kakkad
Start Date
10 Jun 2024
23 Feb 2021
Description | The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 20 Jun 2019 | 25 Jun 2018 |
Description
The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
20 Jun 2019
25 Jun 2018